# A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)

Study · id `cardio:ct-nct05018650` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05018650](<https://clinicaltrials.gov/study/NCT05018650>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05018650

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.

## Technical summary

Registry record NCT05018650. Randomized; no masking; primary purpose treatment. Start 2021-12-21 (actual); primary completion 2024-02-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 250 participants (enrolled count; ClinicalTrials.gov record NCT05018650, source copy `cardio:ctgov-nct05018650-2025-04-09`, retrieved 2026-10-26)
- Started: 2021-12-21 (actual) (ClinicalTrials.gov record NCT05018650, source copy `cardio:ctgov-nct05018650-2025-04-09`, retrieved 2026-10-26)
- Primary completion: 2024-02-19 (actual) (ClinicalTrials.gov record NCT05018650, source copy `cardio:ctgov-nct05018650-2025-04-09`, retrieved 2026-10-26)
- Completion: 2024-05-22 (actual) (ClinicalTrials.gov record NCT05018650, source copy `cardio:ctgov-nct05018650-2025-04-09`, retrieved 2026-10-26)
- Countries: United States; New Zealand (ClinicalTrials.gov record NCT05018650, source copy `cardio:ctgov-nct05018650-2025-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05018650-2025-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)
- Condition: Acute Ischemic Stroke
- Intervention (Device): Route 92 Medical Reperfusion System
- Lead sponsor: Route 92 Medical, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: SUMMIT MAX: A Randomized Trial of the Super Large Bore HiPoint Reperfusion System Versus Vecta System for Aspiration Thrombectomy (`cardio:pubmed-40395106`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0b7c169d73b44f42f9c80184cb3bbb1ecc68f189ee4f15af92bb4a86c3908dee
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
